Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study With an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ifetroban (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DMD; FIGHT DMD
  • Sponsors Cumberland Pharmaceuticals

Most Recent Events

  • 05 Aug 2025 According to a Cumberland Pharmaceuticals media release, in June 2025, Cumberland completed the comprehensive analysis of the study results, completed its clinical study report and submitted it to the FDA along with a request for an end-of-Phase II meeting.
  • 23 Jun 2025 According to a Cumberland Pharmaceuticals media release, FIGHT DMD Trial Principal Investigator Larry W. Markham presented result data from this study at Riley Children's Hospital and the Indiana University School of Medicine, as part of the "Therapies that Slow Progression" conference session.
  • 23 Jun 2025 12 month results data presented in the Cumberland Pharmaceutical Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top